

Grace Lai-Hung Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3766779/publications.pdf>

Version: 2024-02-01

419
papers

26,517
citations

4658

85
h-index

8630

146
g-index

422
all docs

422
docs citations

422
times ranked

20555
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	7.3	1,052
2	Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. <i>Gut</i> , 2021, 70, 698-706.	12.1	818
3	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
4	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1317-25.	7.1	543
5	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010, 59, 969-974.	12.1	538
6	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
7	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	12.1	423
8	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	7.3	408
9	Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 461-478.	17.8	400
10	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	12.1	386
11	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	2.0	363
12	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 – Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
13	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	4.4	320
14	Systematic review with meta-analysis: noninvasive assessment of nonalcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 254-269.	3.7	320
15	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet</i> , The, 2007, 369, 1621-1626.	13.7	297
16	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.4	292
17	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
18	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	7.3	267

#	ARTICLE	IF	CITATIONS
19	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis â€œ A Longitudinal Study. PLoS ONE, 2013, 8, e62885.	2.5	266
20	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65, 54-64.	7.3	260
21	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. Journal of Hepatology, 2013, 59, 536-542.	3.7	254
22	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology, 2013, 12, 256-262.	1.5	252
23	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut, 2011, 60, 1721-1727.	12.1	248
24	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. American Journal of Gastroenterology, 2015, 110, 1306-1314.	0.4	240
25	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews, 2020, 33, .	13.6	239
26	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. Journal of Hepatology, 2014, 60, 339-345.	3.7	227
27	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology, 2010, 52, 1232-1241.	7.3	226
28	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut, 2011, 60, 829-836.	12.1	219
29	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScanÂ®. Journal of Hepatology, 2012, 56, 833-839.	3.7	218
30	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. Annals of Surgical Oncology, 2015, 22, 4138-4148.	1.5	206
31	Bacterial Microbiota Profiling in Gastritis without Helicobacter pylori Infection or Non-Steroidal Anti-Inflammatory Drug Use. PLoS ONE, 2009, 4, e7985.	2.5	204
32	International incidence and mortality trends of liver cancer: a global profile. Scientific Reports, 2017, 7, 45846.	3.3	199
33	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut, 2009, 58, 111-117.	12.1	198
34	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology, 2012, 56, 1363-1370.	3.7	198
35	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 69, 1349-1356.	3.7	198
36	High serum interleukinâ€6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. International Journal of Cancer, 2009, 124, 2766-2770.	5.1	197

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	3.7	196
38	Fatty Pancreas, Insulin Resistance, and Î²-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.4	194
39	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Cut</i> , 2015, 64, 667-672.	12.1	185
40	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	4.4	181
41	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
42	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	3.7	173
43	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	1.3	171
44	Long-Term Follow-Up of Patients with Obscure Gastrointestinal Bleeding After Negative Capsule Endoscopy. <i>American Journal of Gastroenterology</i> , 2006, 101, 1224-1228.	0.4	166
45	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1104-1112.	3.7	159
46	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	1.3	156
47	Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment. <i>Gastroenterology</i> , 2013, 144, 933-944.	1.3	155
48	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	8.1	152
49	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	2.8	152
50	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	2.8	151
51	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	3.7	147
52	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	4.4	143
53	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
54	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (<sc>NAFLD</sc>) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 447-456.	3.7	132

#	ARTICLE	IF	CITATIONS
55	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	8.1	130
56	High Incidence of Mortality and Recurrent Bleeding in Patients With <i>Helicobacter pylori</i> –Negative Idiopathic Bleeding Ulcers. <i>Gastroenterology</i> , 2009, 137, 525-531.	1.3	128
57	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 300-305.	2.8	127
58	Efficacy of Cap-Assisted Colonoscopy in Comparison With Regular Colonoscopy: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2009, 104, 41-46.	0.4	125
59	<i>PNPLA3</i> gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	2.8	125
60	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 236-242.	3.7	122
61	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	12.1	121
62	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 278-285.	3.7	120
63	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	4.4	119
64	The Asia–Pacific Working Party on Non–alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
65	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014, 59, 986-995.	7.3	114
66	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 883-893.	3.7	113
67	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	12.1	113
68	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	3.7	112
69	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1095-1103.	3.7	110
70	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	4.0	110
71	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	3.7	110
72	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 387-396.	3.7	108

#	ARTICLE	IF	CITATIONS
73	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008, 28, 79-87.	3.9	105
74	Histone Deacetylase HDAC8 Promotes Insulin Resistance and β -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 4803-4816.	0.9	105
75	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	2.8	104
76	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	3.7	104
77	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???.	0.4	101
78	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	7.3	101
79	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	7.3	100
80	Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients. <i>Antiviral Therapy</i> , 2011, 16, 1249-1257.	1.0	100
81	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1323-1331.	3.7	98
82	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	4.2	96
83	<i>PNPLA3</i> gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 532-539.	3.7	95
84	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	2.8	95
85	Modelling NAFLD disease burden in four Asian regions 2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	3.7	92
86	Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 517-526.	3.7	89
87	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1215-1222.	3.7	88
88	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.4	83
89	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
90	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	3.7	83

#	ARTICLE	IF	CITATIONS
91	Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. <i>Lancet, The</i> , 2017, 389, 2375-2382.	13.7	83
92	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	1.0	82
93	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	8.1	82
94	Update of liver fibrosis and steatosis with transient elastography (Fibroscan). <i>Gastroenterology Report</i> , 2013, 1, 19-26.	1.3	80
95	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	4.4	80
96	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 793-802.	3.7	79
97	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015, 62, 684-693.	7.3	77
98	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	3.7	77
99	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	2.5	77
100	Transient elastography: Kill two birds with one stone?. <i>World Journal of Hepatology</i> , 2013, 5, 264.	2.0	77
101	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	4.4	75
102	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	3.9	75
103	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	3.7	72
104	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.4	72
105	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	4.4	70
106	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 128-141.	8.9	70
107	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	3.7	69
108	How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?. <i>Journal of Hepatology</i> , 2022, 76, 1249-1262.	3.7	69

#	ARTICLE	IF	CITATIONS
109	Changes in Crohn's disease phenotype over time in the Chinese population: Validation of the Montreal classification system. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 536-541.	1.9	68
110	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017, 5, 76-85.	3.8	67
111	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.4	67
112	Lymphoepithelioma-like Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 304-312.	3.7	66
113	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, 5214.	12.8	66
114	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	4.4	64
115	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2803-2820.	1.5	63
116	Inter-observer variations on interpretation of capsule endoscopies. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 283-286.	1.6	62
117	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.4	62
118	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	3.7	61
119	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 197-208.	3.7	61
120	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018, 38, 503-514.	3.9	61
121	Genetic polymorphisms of adiponectin and tumor necrosis factor- α and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	2.8	60
122	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	3.7	60
123	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018, 64, 1239-1249.	3.2	60
124	Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage. <i>Gastroenterology</i> , 2016, 151, 271-277.	1.3	59
125	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 984-992.	3.7	59
126	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	7.3	59

#	ARTICLE	IF	CITATIONS
127	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2022, 76, 726-734.	3.7	59
128	Significant positive association of endotoxemia with histological severity in 237 patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 175-182.	3.7	58
129	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	4.0	58
130	Bacterial endotoxin and nonalcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 731-740.	3.7	57
131	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
132	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.	3.7	54
133	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	54
134	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	3.7	54
135	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007, 13, 1228-1235.	2.4	53
136	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	4.4	52
137	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020, 71, 444-455.	7.3	52
138	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	4.4	51
139	Antiviral therapy improves posthepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 199-208.	3.7	51
140	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 411-421.	3.7	51
141	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	3.7	49
142	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBsAg seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1326-1335.	3.7	48
143	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1001-1010.	3.7	48
144	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	4.4	48

#	ARTICLE	IF	CITATIONS
145	DATA-GRU: Dual-Attention Time-Aware Gated Recurrent Unit for Irregular Multivariate Time Series. Proceedings of the AAAI Conference on Artificial Intelligence, 2020, 34, 930-937.	4.9	48
146	Unmet need in chronic hepatitis B management. Clinical and Molecular Hepatology, 2019, 25, 172-180.	8.9	48
147	Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2010, 32, 1059-1068.	3.7	47
148	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Alimentary Pharmacology and Therapeutics, 2018, 47, 989-1000.	3.7	47
149	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 136-145.e6.	4.4	47
150	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2009, 7, 1113-1120.	4.4	46
151	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clinical and Molecular Hepatology, 2018, 24, 108-113.	8.9	46
152	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. BJU International, 2014, 114, 754-760.	2.5	45
153	Current Knowledge of Occult Hepatitis B Infection and Clinical Implications. Seminars in Liver Disease, 2019, 39, 249-260.	3.6	45
154	Repeat-Screening Colonoscopy 5 Years After Normal Baseline-Screening Colonoscopy in Average-Risk Chinese: A Prospective Study. American Journal of Gastroenterology, 2009, 104, 2028-2034.	0.4	44
155	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1363-1369.	2.8	44
156	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. Clinical Gastroenterology and Hepatology, 2017, 15, 1453-1460.e1.	4.4	42
157	Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding. Alimentary Pharmacology and Therapeutics, 2019, 49, 912-918.	3.7	41
158	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology, 2021, 74, 1750-1765.	7.3	41
159	Prediction of fibrosis progression in chronic viral hepatitis. Clinical and Molecular Hepatology, 2014, 20, 228.	8.9	41
160	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology, 2022, 76, 469-482.	7.3	41
161	Predictors of Treatment Response in Chronic Hepatitis B. Drugs, 2009, 69, 2167-2177.	10.9	40
162	HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. American Journal of Gastroenterology, 2017, 112, 1111-1119.	0.4	40

#	ARTICLE	IF	CITATIONS
163	Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1787-1794.	2.8	40
164	Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. <i>Nucleic Acids Research</i> , 2018, 46, 8832-8847.	14.5	40
165	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40
166	Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 543-550.	2.8	40
167	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	4.0	40
168	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 802-813.	3.7	39
169	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	2.8	39
170	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	5.8	39
171	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 891-898.	3.7	38
172	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	1.0	38
173	Gastroprotective Therapy Does Not Improve Outcomes of Patients With Helicobacter pylori-Negative Idiopathic Bleeding Ulcers. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1124-1129.	4.4	38
174	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 6515.	3.3	38
175	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	4.2	38
176	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	3.4	38
177	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.4	37
178	Current developments in nucleoside/nucleotide analogues for hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 607-622.	3.0	36
179	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	2.8	35
180	Initial experience of real-time capsule endoscopy in monitoring progress of the videocapsule through the upper GI tract. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 1211-1214.	1.0	34

#	ARTICLE	IF	CITATIONS
181	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014, 60, 809-815.	3.7	34
182	A new screening strategy for varices by liver and spleen stiffness measurement (<scp>LSSM</scp>) in cirrhotic patients: A randomized trial. <i>Liver International</i> , 2018, 38, 636-644.	3.9	34
183	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-499.	1.0	34
184	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019, 70, 971-981.	7.3	33
185	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2022, 42, 149-160.	3.9	33
186	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 571-579.	1.0	33
187	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis <scp>B</scp>. <i>Journal of Viral Hepatitis</i> , 2014, 21, 825-834.	2.0	32
188	Non-invasive assessments for liver fibrosis: The crystal ball we long for. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1009-1015.	2.8	32
189	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	32
190	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011, 31, 1047-1053.	3.9	31
191	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016, 17, 538-546.	1.5	31
192	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 145-153.	3.7	30
193	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, 2205-2211.	0.4	29
194	Personalized management of cirrhosis by non-invasive tests of liver fibrosis. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 200.	8.9	29
195	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. <i>Annals of Hepatology</i> , 2013, 12, 402-412.	1.5	28
196	Targeted hepatitis <scp>C</scp> screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.8	28
197	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	2.8	28
198	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	7.7	28

#	ARTICLE	IF	CITATIONS
199	Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2014-2022.e4.	4.4	28
200	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	2.5	28
201	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-471.	1.0	28
202	Virological Response to Different Combination Regimes of Peginterferon α -2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-823.	1.0	28
203	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	2.8	27
204	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	4.2	27
205	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	12.1	27
206	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	5.8	26
207	Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2011, 23, 155-e31.	3.0	25
208	Efficient Shapelet Discovery for Time Series Classification. <i>IEEE Transactions on Knowledge and Data Engineering</i> , 2022, 34, 1149-1163.	5.7	25
209	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.4	25
210	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	4.4	24
211	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1629-1638.	0.4	24
212	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	7.3	24
213	Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 63-69.	2.8	23
214	Treatment of non-alcoholic steatohepatitis with <i>hyllanthus urinaria</i> : A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	2.8	23
215	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016, 64, 1507-1517.	7.3	23
216	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk—a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1213-1224.	3.7	23

#	ARTICLE	IF	CITATIONS
217	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 271-279.	3.9	23
218	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	3.7	23
219	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	3.9	22
220	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	2.8	22
221	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	2.2	22
222	Risks of post-colonoscopy polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. <i>Gut</i> , 2022, 71, 100-110.	12.1	22
223	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. <i>Clinical Chemistry</i> , 2022, 68, 1151-1163.	3.2	22
224	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: A seven-year follow-up study. <i>Journal of Medical Virology</i> , 2009, 81, 224-229.	5.0	21
225	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	2.9	21
226	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
227	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	4.4	21
228	Metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 716-726.	3.7	20
229	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	2.9	20
230	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	7.3	20
231	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	2.5	20
232	Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3541-3547.	2.3	19
233	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2210-2219.	2.8	19
234	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 470-480.	3.7	19

#	ARTICLE	IF	CITATIONS
235	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	4.4	18
236	Collateral Effect of Coronavirus Disease 2019 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases: A Territory-wide Observational Study in Hong Kong. <i>Gastroenterology</i> , 2020, 159, 1979-1981.e3.	1.3	18
237	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.9	18
238	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	5.1	18
239	Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea. A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 493-501.	5.6	18
240	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	3.4	18
241	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17
242	Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 6006.	3.3	17
243	Eliminating hepatitis B virus as a global health threat. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1313-1314.	9.1	17
244	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir – A prospective study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 126-135.	2.0	17
245	Explainable Uncertainty-Aware Convolutional Recurrent Neural Network for Irregular Medical Time Series. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , 2021, 32, 4665-4679.	11.3	17
246	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	2.0	17
247	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	17
248	Advances in the diagnosis and treatment of liver fibrosis. <i>Hepatoma Research</i> , 2017, 3, 156.	1.5	17
249	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , 2021, 11, e052310.	1.9	17
250	Non-invasive tests of non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2022, 135, 532-546.	2.3	17
251	Management of hepatitis B virus reactivation due to treatment of COVID-19. <i>Hepatology International</i> , 2022, 16, 257-268.	4.2	17
252	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16

#	ARTICLE	IF	CITATIONS
253	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	2.8	16
254	Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB – Is one NUC better than the other?. <i>Journal of Hepatology</i> , 2019, 71, 453-455.	3.7	16
255	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2019, 70, 660-666.	5.8	16
256	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	6.1	16
257	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 972-981.	3.7	15
258	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018, 38, 1911-1919.	3.9	15
259	Differential Impacts of Multimorbidity on COVID-19 Severity across the Socioeconomic Ladder in Hong Kong: A Syndemic Perspective. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8168.	2.6	15
260	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 592-598.	2.8	14
261	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	3.7	14
262	Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. <i>Gut</i> , 2020, 69, 652-657.	12.1	14
263	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.8	14
264	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020, 5, 1129-1138.	0.8	14
265	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	4.2	14
266	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	8.9	14
267	Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , 2022, 76, 186-194.	3.7	14
268	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-99.	1.0	14
269	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	2.8	13
270	Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study. <i>Gut</i> , 2021, , gutjnl-2020-323054.	12.1	13

#	ARTICLE	IF	CITATIONS
271	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	1.0	12
272	Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 9-12.	2.3	12
273	Noninvasive assessments of liver fibrosis with transient elastography and <sc>H</sc>ui index predict survival in patients with chronic hepatitis <sc>B</sc>. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	2.8	12
274	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016, 62, S298-S305.	5.8	12
275	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	2.2	12
276	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	3.3	12
277	UA-CRNN: Uncertainty-Aware Convolutional Recurrent Neural Network for Mortality Risk Prediction. , 2019, , .		12
278	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	8.9	12
279	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	4.9	12
280	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon $\hat{\pm}2a$ (40 kDa; PEGASYSA [®]). <i>Antiviral Therapy</i> , 2008, 13, 555-562.	1.0	12
281	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	4.4	11
282	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg $\hat{\epsilon}$ negative chronic hepatitis B. <i>Liver International</i> , 2020, 40, 549-557.	3.9	11
283	Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound. <i>World Journal of Radiology</i> , 2009, 1, 25.	1.1	11
284	Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 571-9.	1.0	11
285	Liver Stiffness Measurement: Simplicity is Prerequisite for Reliability. <i>Gastroenterology</i> , 2013, 144, 243-244.	1.3	10
286	Gastrointestinal Involvement in Asymptomatic Crohn $\hat{\epsilon}$ TM's Disease Patients in Two Areas of Emerging Disease: Asia and Eastern Europe. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1401-1406.	1.3	10
287	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory $\hat{\epsilon}$ wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	2.8	10
288	LBO-03-Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e128.	3.7	10

#	ARTICLE	IF	CITATIONS
289	Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. <i>Journal of Gastroenterology</i> , 2020, 55, 1023-1036.	5.1	10
290	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.9	10
291	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. <i>BMC Gastroenterology</i> , 2016, 16, 100.	2.0	9
292	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	2.5	9
293	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	4.3	9
294	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London)</i> , 2019, 10, 10.	0.5	8
295	How does hepatitis B virus infection react to hepatocellular carcinoma treatment?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1-2.	2.8	8
296	Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine. <i>Antiviral Therapy</i> , 2013, 18, 671-680.	1.0	8
297	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2202-2209.	2.8	8
298	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135,395 patients from 2000 to 2017. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3487-3499.	2.8	8
299	Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021, 19, 329-337.	1.8	8
300	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 554-561.	8.9	8
301	Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-71.	1.0	8
302	Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-23.	1.0	8
303	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012, 57, 221-231.	2.3	7
304	Impact of <i>IL28B</i> and <i>PNPLA3</i> polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1040-1048.	2.8	7
305	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1190-1199.	3.7	7
306	A LEAN treatment for non-alcoholic steatohepatitis. <i>Lancet</i> , 2016, 387, 628-630.	13.7	7

#	ARTICLE	IF	CITATIONS
307	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	4.2	7
308	Quantitative Subtyping of Hepatitis B Virus Reveals Complex Dynamics of Ymdd Motif Mutants Development during Long-Term Lamivudine Therapy. <i>Antiviral Therapy</i> , 2006, 11, 1041-1050.	1.0	7
309	Cerebellum vasculopathy and normal tension glaucoma in systemic lupus erythematosus: report of a case and review of the literature. <i>Rheumatology International</i> , 2006, 27, 101-102.	3.0	6
310	Huge Adrenal Hemangioma: A Rare Cause of Deceivingly High Liver Stiffness Measurement by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e37-e38.	4.4	6
311	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1071-1078.	2.8	6
312	Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. <i>PLoS ONE</i> , 2017, 12, e0181603.	2.5	6
313	Non-alcoholic fatty liver disease in Asia: How is it different from the West?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1267-1268.	2.8	6
314	Macromolecular proton fraction mapping based on spin-lock magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 3157-3171.	3.0	6
315	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 128.	2.0	6
316	Hepatitis B management of acute infection and active inflammation in pregnancy—a hepatologist's perspective. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 68, 54-65.	2.8	6
317	Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, 20, 78-84.	1.8	6
318	Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 273-277.	8.9	6
319	Importance-aware personalized learning for early risk prediction using static and dynamic health data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 713-726.	4.4	6
320	Who will have the best response to entecavir?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 5-7.	2.8	5
321	Editorial: when and how to use steatosis biomarkers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1359-1360.	3.7	5
322	Is Obeticholic Acid the Solution to Nonalcoholic Steatohepatitis?. <i>Gastroenterology</i> , 2015, 148, 851-852.	1.3	5
323	The emerging role of big data in gastroenterology and hepatology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 307-308.	2.8	5
324	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	5.0	5

#	ARTICLE	IF	CITATIONS
325	How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?. The Lancet Gastroenterology and Hepatology, 2020, 5, 103-105.	8.1	5
326	Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World Journal of Hepatology, 2015, 7, 2133.	2.0	5
327	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. Journal of Medical Virology, 2022, 94, 4440-4448.	5.0	5
328	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. Journal of Hepatology, 2011, 55, 497.	3.7	4
329	SAT-288-Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 70, e763-e764.	3.7	4
330	Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues". Journal of Hepatology, 2019, 70, 796-797.	3.7	4
331	Monocyte-Derived Hepatocyte-Like Cell Test: A Novel Tool for in vitro Identification of Drug-Induced Liver Injury in Patients with Herbal or Dietary Supplements. Digestion, 2021, 102, 650-653.	2.3	4
332	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1610-1618.	2.8	4
333	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. The Lancet Gastroenterology and Hepatology, 2021, 6, 258-260.	8.1	4
334	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clinical Gastroenterology and Hepatology, 2022, 20, 874-885.e4.	4.4	4
335	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. , 2021, , .		4
336	A Hybrid Residual Network and Long Short-Term Memory Method for Peptic Ulcer Bleeding Mortality Prediction. AMIA ... Annual Symposium proceedings, 2018, 2018, 998-1007.	0.2	4
337	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. BMJ Open, 2021, 11, e052310.	1.9	4
338	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). Antiviral Therapy, 2008, 13, 555-62.	1.0	4
339	No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1284-1289.	2.8	4
340	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2022, 28, 1563-1573.	3.3	4
341	Prolonged Esophageal Transit During Wireless Capsule Endoscopy: A Series of Five Cases and Analysis of Risk Factors. Journal of Clinical Gastroenterology, 2006, 40, 176.	2.2	3
342	Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice. Clinical Liver Disease, 2013, 2, 8-10.	2.1	3

#	ARTICLE	IF	CITATIONS
343	Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1135-7.	2.3	3
344	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , 2019, 39, 494-502.	3.9	3
345	Value of FIB-4 and NAFLD fibrosis scores for screening of liver fibrosis in the general population. <i>Journal of Hepatology</i> , 2020, 73, S414-S415.	3.7	3
346	Efficient Shapelet Discovery for Time Series Classification (Extended Abstract). , 2021, , .		3
347	Alanine Aminotransferase Level: The Road to Normal in 2021. <i>Hepatology Communications</i> , 2021, 5, 1807-1809.	4.3	3
348	Effectiveness of prophylactic clipping in preventing postpolypectomy bleeding in oral anticoagulant users: a propensity-score analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 96, 530-542.e1.	1.0	3
349	Commentary: coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1236-1237.	3.7	2
350	Is Antiviral Drug-Induced Hepatitis B Surface Antigen Loss Durable?. <i>Gastroenterology</i> , 2014, 147, 1435-1436.	1.3	2
351	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2015, 9, 481-483.	4.2	2
352	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 260-262.	8.1	2
353	Reply. <i>Gastroenterology</i> , 2020, 158, 2312-2313.	1.3	2
354	Temporal matrix completion with locally linear latent factors for medical applications. <i>Artificial Intelligence in Medicine</i> , 2020, 107, 101883.	6.5	2
355	Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond). <i>Current Hepatology Reports</i> , 2020, 19, 285-292.	0.9	2
356	Neurological diseases and risk of mortality in patients with COVID-19 and SARS: a territory-wide study in Hong Kong. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1356-1358.	1.9	2
357	IDDF2021-ABS-0077 – Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment. , 2021, , .		2
358	Medical therapy for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1135-1136.	3.7	1
359	PWE-293 – Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general population – a randomised controlled trial. <i>Gut</i> , 2012, 61, A417.1-A417.	12.1	1
360	Commentary: predicting survival in hepatocellular carcinoma patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 680-680.	3.7	1

#	ARTICLE	IF	CITATIONS
361	Noninvasive algorithms for liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 310-311.	3.7	1
362	Tertiary Prevention of HBV-related HCC in Asia. <i>Current Hepatitis Reports</i> , 2013, 12, 157-164.	0.3	1
363	Editorial: metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 983-983.	3.7	1
364	Reply. <i>Hepatology</i> , 2014, 60, 1797-1798.	7.3	1
365	Reply. <i>Hepatology</i> , 2016, 64, 685-686.	7.3	1
366	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. <i>Current Hepatology Reports</i> , 2017, 16, 97-104.	0.9	1
367	How long will it take to eliminate HCC risk in patients with chronic hepatitis B patients with potent antivirals?. <i>AME Medical Journal</i> , 2017, 2, 141-141.	0.4	1
368	PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS \geq 4) and significant fibrosis (F \geq 2). <i>Journal of Hepatology</i> , 2019, 70, e134-e135.	3.7	1
369	HCV elimination in Hong Kong Non-government organisation (NGO) activities. <i>Global Health & Medicine</i> , 2021, 3, 283-287.	1.4	1
370	Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 87.	8.1	1
371	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.6	1
372	Cooperative Joint Attentive Network for Patient Outcome Prediction on Irregular Multi-Rate Multivariate Health Data. , 2021, , .		1
373	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021, 4, e352.	1.5	1
374	Drug-drug interactions with direct-acting antivirals less is more. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 81-82.	8.9	1
375	Tips for Responding to Reviewers' Comments from an Editor's or Reviewer's Points of View. <i>Gut and Liver</i> , 2019, 13, 7-10.	2.9	1
376	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	3.7	1
377	Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy. <i>Antiviral Therapy</i> , 2006, 11, 1041-9.	1.0	1
378	Anasarca secondary to problems in three organs: one man with three diseases?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1651-1653.	0.7	0

#	ARTICLE	IF	CITATIONS
379	Rules for Predicting Safe Early Hospital Discharge for Patients with Upper Gastrointestinal Bleeding: A Phase I (Derivation Phase) Study. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB153.	1.0	0
380	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	12.1	0
381	Commentary: time to update the <sc>ALT</sc> cutâ€off?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 682-683.	3.7	0
382	Role of Anti-Viral Therapy on Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC). , 0, , .		0
383	Reply. <i>Hepatology</i> , 2016, 64, 1820-1821.	7.3	0
384	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 171-172.	3.7	0
385	Letter: which patients with hepatitis B virusâ€related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 910-910.	3.7	0
386	Reply. <i>Hepatology</i> , 2017, 65, 1780-1780.	7.3	0
387	Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 560-561.	3.7	0
388	Reply to: â€œRisk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceâ€• <i>Journal of Hepatology</i> , 2018, 68, 208-209.	3.7	0
389	IDDF2018-ABS-0058â€…Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b â€“ a territory-wide study of 21,182 subjects. , 2018, , .		0
390	Letter: chronic kidney disease risk in patients with chronic hepatitis Bâ€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1324-1324.	3.7	0
391	SAT-142-Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study. <i>Journal of Hepatology</i> , 2019, 70, e693.	3.7	0
392	THU-237-Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017. <i>Journal of Hepatology</i> , 2019, 70, e269.	3.7	0
393	FRI-164-Prognostic value of various liver scoring systems in cirrhotic chronic hepatitis B patients with and without tenofovir disoproxil fumarate treatment. <i>Journal of Hepatology</i> , 2019, 70, e461.	3.7	0
394	FRI-192-Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death. <i>Journal of Hepatology</i> , 2019, 70, e475.	3.7	0
395	SAT-147-Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e696.	3.7	0
396	SAT-072-Predict improvement of liver cirrhosis after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e659.	3.7	0

#	ARTICLE	IF	CITATIONS
397	IDDF2019-ABS-0199â€¦The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
398	Reply to Sun et al. Clinical Infectious Diseases, 2020, 70, 2748-2749.	5.8	0
399	Reply:. Hepatology, 2020, 71, 1134-1134.	7.3	0
400	HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1661-1662.	2.8	0
401	Reply to Hoffmann and Wolf. Clinical Infectious Diseases, 2021, 73, e1782-e1783.	5.8	0
402	Individual patient data meta-analysis on controlled attenuation parameter for the XL probe in obese patients. Journal of Hepatology, 2020, 73, S437-S438.	3.7	0
403	Risk of hepatitis flare in inflammatory bowel disease patients with previous hepatitis B virus exposure - results from a territory-wide Hong Kong ibd registry study. Journal of Hepatology, 2020, 73, S589-S590.	3.7	0
404	Evaluation of page-b and modified page-b scores to guide hepatocellular carcinoma surveillance in chronic hepatitis B patients on antiviral therapy - a territory-wide study of 32,150 subjects. Journal of Hepatology, 2020, 73, S599-S600.	3.7	0
405	Reply to: â€œHepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the pageâ€• Journal of Hepatology, 2020, 73, 729-730.	3.7	0
406	Editorial: increasing burden of nonalcoholic fatty liver diseaseâ€”a call to action. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1430-1432.	3.7	0
407	Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 315-316.	3.7	0
408	Reply to Boglione et al. Clinical Infectious Diseases, 2020, 71, 1584-1585.	5.8	0
409	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong. Kidney360, 2021, 2, 721-728.	2.1	0
410	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 2684-2685.	4.4	0
411	Liverâ€™heart connection in diabetes mellitus. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1385-1386.	2.8	0
412	Reply. Hepatology, 2022, 75, 1051-1052.	7.3	0
413	Targeting an energy sensor to prevent energy excess in the liver. The Lancet Gastroenterology and Hepatology, 2021, 6, 876-877.	8.1	0
414	Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. AIMS Medical Science, 2016, 3, 162-178.	0.4	0

#	ARTICLE	IF	CITATIONS
415	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.. Journal of Clinical Oncology, 2020, 38, 508-508.	1.6	0
416	Prediction of HCC Using Liver Stiffness Measurements. , 2020, , 375-382.		0
417	IDDF2020-ABS-0194â€¦Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study. , 2020, ,		0
418	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. GastroHep, 2022, 2022, 1-13.	0.6	0
419	Reply. Hepatology, 2022, 76, E34-E35.	7.3	0